The goal of this pilot clinical trial is to learn if a faster brain stimulation schedule is practical, safe, tolerable, and acceptable. This study looks at accelerated intermittent theta burst stimulation, or accelerated iTBS. This is a non-invasive type of magnetic brain stimulation. This study is for adults with post-traumatic stress disorder (PTSD) and major depressive disorder (MDD). The main questions this study aims to answer are: 1. Can participants complete six short brain stimulation sessions per day for five days? 2. Is this treatment schedule safe and tolerable for participants? 3. What changes occur in depression symptoms, PTSD symptoms, anxiety, quality of life, and brain activity over time? Participants will: 1. Complete health screening and baseline assessments. 2. Receive six short sessions of magnetic brain stimulation per day for five days. 3. Have their brain activity measured using an EEG recording. 4. Return for a post-treatment assessment at Week 2 and follow-up visits at Week 5 and Week 12.
Age range
18 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
Recruitment rate
Timeframe: Study recruitment period, up to 12 months
Consent rate
Timeframe: Study recruitment period, up to 12 months
Treatment adherence
Timeframe: Treatment Days 1 through 5
Retention through Week 12 follow-up
Timeframe: Baseline through Week 12
Adverse events
Timeframe: Treatment Days 1 through Week 12
Serious adverse events
Timeframe: Treatment Days 1 through Week 12
Discontinuations due to adverse events
Timeframe: Treatment Days 1 through Week 12
Participant satisfaction with accelerated iTBS
Timeframe: Week 2, Week 5, and Week 12
Participant feedback on accelerated iTBS
Timeframe: Week 2, Week 5, and Week 12